Log in

NASDAQ:GOSSGossamer Bio Stock Price, Forecast & News

$13.09
0.00 (0.00 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.90
Now: $13.09
$13.46
50-Day Range
$11.53
MA: $12.54
$13.27
52-Week Range
$7.52
Now: $13.09
$27.15
Volume279,900 shs
Average Volume609,127 shs
Market Capitalization$868.65 million
P/E RatioN/A
Dividend YieldN/A
Beta1.15
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.11 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GOSS
CUSIPN/A
CIKN/A
Phone858-922-0718

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.34 per share

Profitability

Net Income$-180,310,000.00

Miscellaneous

Employees118
Market Cap$868.65 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive GOSS News and Ratings via Email

Sign-up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.

Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions

How has Gossamer Bio's stock been impacted by COVID-19 (Coronavirus)?

Gossamer Bio's stock was trading at $10.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GOSS stock has increased by 23.6% and is now trading at $13.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Gossamer Bio?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gossamer Bio.

When is Gossamer Bio's next earnings date?

Gossamer Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Gossamer Bio.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio Inc (NASDAQ:GOSS) announced its earnings results on Tuesday, May, 12th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.07. View Gossamer Bio's earnings history.

What price target have analysts set for GOSS?

8 Wall Street analysts have issued 12-month target prices for Gossamer Bio's shares. Their forecasts range from $21.00 to $36.00. On average, they anticipate Gossamer Bio's share price to reach $29.50 in the next year. This suggests a possible upside of 125.4% from the stock's current price. View analysts' price targets for Gossamer Bio.

Has Gossamer Bio been receiving favorable news coverage?

News articles about GOSS stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gossamer Bio earned a daily sentiment score of -1.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Gossamer Bio.

Are investors shorting Gossamer Bio?

Gossamer Bio saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 5,850,000 shares, an increase of 29.4% from the May 31st total of 4,520,000 shares. Based on an average daily volume of 617,000 shares, the short-interest ratio is currently 9.5 days. Currently, 12.8% of the company's shares are sold short. View Gossamer Bio's Current Options Chain.

Who are some of Gossamer Bio's key competitors?

What other stocks do shareholders of Gossamer Bio own?

Who are Gossamer Bio's key executives?

Gossamer Bio's management team includes the following people:
  • Mr. Faheem Hasnain, Co-Founder & Exec. Chairman (Age 61)
  • Dr. Sheila K. Gujrathi M.D., Co-Founder, Pres, CEO & Director (Age 49)
  • Mr. Bryan Giraudo, Chief Financial Officer (Age 43)
  • Mr. Christian Waage, Exec. VP, Gen. Counsel & Sec. (Age 52)
  • Dr. Jakob Dupont, Chief Medical Officer (Age 54)

When did Gossamer Bio IPO?

(GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

How do I buy shares of Gossamer Bio?

Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $13.09.

How big of a company is Gossamer Bio?

Gossamer Bio has a market capitalization of $868.63 million. The company earns $-180,310,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Gossamer Bio employs 118 workers across the globe.

What is Gossamer Bio's official website?

The official website for Gossamer Bio is www.gossamerbio.com.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at 858-922-0718.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.